Literature DB >> 26029733

Tumor cell p38 MAPK: A trigger of cancer bone osteolysis.

Huan Liu1, Jin He1, Jing Yang2.   

Abstract

Osteolytic bone destruction is a hallmark of bone-metastatic cancers. Current therapy is unable to completely cure or prevent this disease in patients. The p38 mitogen-activated protein kinase (MAPK) affects a diverse range of intracellular responses with well-known roles in development, cell-cycle and differentiation, inflammation, apoptosis, senescence, and tumorigenesis. This article is an overview of the contribution of tumor cell-expressed p38 MAPK to the regulation of osteoclastogenesis, osteoblastogenesis, and osteolyticbone lesions.

Entities:  

Keywords:  bone destruction; breast cancer; cytokines; multiple myeloma; p38 MAPK

Year:  2015        PMID: 26029733      PMCID: PMC4448135          DOI: 10.14800/ccm.464

Source DB:  PubMed          Journal:  Cancer Cell Microenviron


  43 in total

1.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  IL-1 mediates TNF-induced osteoclastogenesis.

Authors:  Shi Wei; Hideki Kitaura; Ping Zhou; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 5.  New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.

Authors:  Christian Peifer; Gerd Wagner; Stefan Laufer
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

6.  Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Authors:  Aaron N Nguyen; Elizabeth G Stebbins; Margaret Henson; Gilbert O'Young; Sun J Choi; Diana Quon; Debby Damm; Mamatha Reddy; Jing Y Ma; Edwin Haghnazari; Ann M Kapoun; Satyanarayana Medicherla; Andy Protter; George F Schreiner; Noriyoshi Kurihara; Judy Anderson; G David Roodman; Tony A Navas; Linda S Higgins
Journal:  Exp Cell Res       Date:  2006-04-04       Impact factor: 3.905

7.  The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Weiguo Zou; Despina Sitara; Michelle Schweitzer; Dorothy Hu; Sutada Lotinun; Yasuyo Sano; Roland Baron; Jin Mo Park; Simon Arthur; Min Xie; Michael D Schneider; Bo Zhai; Steven Gygi; Roger Davis; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

8.  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Authors:  Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

9.  Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Authors:  Karin Vanderkerken; Satya Medicherla; Les Coulton; Hendrik De Raeve; Angelo Willems; Michelle Lawson; Ben Van Camp; Andrew A Protter; Linda S Higgins; Eline Menu; Peter I Croucher
Journal:  Cancer Res       Date:  2007-05-10       Impact factor: 12.701

10.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more
  7 in total

1.  Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.

Authors:  Qingqing Mo; Yu Zhang; Xin Jin; Yue Gao; Yuan Wu; Xing Hao; Qinglei Gao; Pingbo Chen
Journal:  Tumour Biol       Date:  2016-09-15

2.  Clinicopathological significance of p38β, p38γ, and p38δ and its biological roles in esophageal squamous cell carcinoma.

Authors:  Shutao Zheng; Chenchen Yang; Tao Liu; Qing Liu; Fang Dai; Ilyar Sheyhidin; Xiaomei Lu
Journal:  Tumour Biol       Date:  2015-12-14

3.  The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.

Authors:  Xin Jin; Qingqing Mo; Yu Zhang; Yue Gao; Yuan Wu; Jing Li; Xing Hao; Ding Ma; Qinglei Gao; Pingbo Chen
Journal:  Cancer Biol Ther       Date:  2016-05-03       Impact factor: 4.742

4.  Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender.

Authors:  Eliana Pivetta; Bruna Wassermann; Pietro Bulian; Agostino Steffan; Alfonso Colombatti; Jerry Polesel; Paola Spessotto
Journal:  Oncotarget       Date:  2015-10-13

5.  Pexmetinib suppresses osteoclast formation and breast cancer induced osteolysis via P38/STAT3 signal pathway.

Authors:  Zhiwei Jie; Shiyu Wang; Qingliang Ma; Yang Shen; Xiangde Zhao; Hejun Yu; Ziang Xie; Chao Jiang
Journal:  J Bone Oncol       Date:  2022-06-11       Impact factor: 4.491

Review 6.  Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Authors:  Hanley N Abramson
Journal:  Oncotarget       Date:  2016-12-06

7.  Roles of p38α and p38β mitogen‑activated protein kinase isoforms in human malignant melanoma A375 cells.

Authors:  Su-Ying Wen; Shi-Yann Cheng; Shang-Chuan Ng; Ritu Aneja; Chih-Jung Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Int J Mol Med       Date:  2019-10-24       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.